Ipamorelin is a peptide selective
ghrelin/growth hormone (GHS) receptor agonist and growth hormone secretagogue.
It is a pentapeptide with the amino acid sequence
Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1.
Ipamorelin significantly increases plasma
growth hormone levels. The drug stimulates endogenous growth hormone production
rather than replacing it. Clinical studies have shown that ipamorelin
stimulates body weight gain in animals.
Like pralmorelin (GHRP-2) and GHRP-6,
ipamorelin does not affect levels of prolactin, follicle-stimulating hormone,
luteinizing hormone, or thyroid-stimulating hormone. However, unlike pralmorelin
(GHRP-2) and GHRP-6, ipamorelin does not stimulate the secretion of
adrenocorticotropic hormone or cortisol, and is highly selective for inducing
growth hormone secretion only.
AREAS OF
APPLICATION
Rehabilitation: accelerates
recovery after surgery, injuries, and fractures, and reduces catabolic
processes (muscle breakdown).
Sports medicine: increases lean muscle mass, improves strength and endurance, and
promotes effective lipolysis (fat burning).
Cosmetology: improves
skin texture and reduces swelling.
DOSAGE AND
APPLICATION
The lyophilized form of ipamorelin is usually
injected subcutaneously into the fatty tissue (often in the abdominal area).
The average recommended dose of ipamorelin is 0.3–0.6 mg per day. Possible
injection frequency: 3 times daily, 0.1–0.2 mg (morning, afternoon, evening).
The course duration is 1–3 months.
To achieve a synergistic effect, MOTS-c can be
combined with other peptides, such as CJC-1295. Consult your doctor regarding
individual dosage selection, administration schedule, and drug compatibility.
